DUBLIN–(BUSINESS WIRE)–The “China
Pharmaceutical Distribution Industry Report, 2019-2025” report
has been added to ResearchAndMarkets.com’s offering.
China’s pharmaceutical distribution industry has sustained steady
growth over the years
By product, western medicine is prevailing in the Chinese pharmaceutical
distribution market, sweeping 73.2% of total sales in 2018; by region,
the east and the central south of China take larger shares, a combined
62.1% in 2018.
In China, a competitive pattern has taken shape that national drug
distributors led by Sinopharm, China Resources Pharmaceutical Group,
Shanghai Pharmaceuticals and Jointown Pharmaceutical Group, and regional
distribution companies such as Nanjing Pharmaceutical, Guangzhou
Pharmaceuticals, Chongqing Pharmaceutical, Huadong Medicine, Sichuan
Kelun Pharmaceutical, Zhejiang Int’l Group, Realcan Pharmaceutical,
Guangzhou Liuzhou Pharmaceutical and Luyan Phapma, compete with each
other.
By the end of 2018, there had been 13,146 drug wholesalers competing
fiercely in China, showing a low market concentration. In 2018, the top
100 by operating revenue commanded 70.7% of China’s pharmaceuticals
market, and the first four leaders occupied 37.6%.
By the end of 2018, there had been 5,985 drugstore chains in possession
of 463,200 retail stores in China, of which 242,560 were chain stores,
taking up 52.4% of the total, up by 2 percentage points on an annualized
basis; 88.3% of stores were directly run by retailers themselves; 72%
were designated medical insurance stores.
In China, leading drug retail chains include Yunnan Hongxiang Yixintang
Pharmaceutical Co, Ltd, Dashenlin Pharmaceutical Group Co, Ltd, LBX
Pharmacy, Yifeng Pharmacy, Sinopharm, China Nepstar Chain Drugstore,
Gansu Zhongyou Health Medicine Co, Ltd, Suzhou Quanyi Health Drugstore
Chain Co, Ltd, Chongqing Tong Jun Ge Co, Ltd. and Yunnan Jianzhijia
Health Drugstore Chain Co, Ltd, among which Chongqing Tong Jun Ge Co,
Ltd. has 10,575 drugstores, the most among all retail chains, and Yunnan
Hongxiang Yixintang Pharmaceutical Co, Ltd. boasts the largest number of
direct-sale stores, numbering 5,758, all of which are directly operated
by the company.
The immense potential of the pharmaceutical distribution industry has
attracted the inrush of capital in recent years, and mergers and
acquisitions occurred frequently. Boosted by capital, drug circulation
companies are gearing from traditional endogenous growth by adding more
products, new stores and developing customers to extensive development
by M&A and restructuring. The industry is becoming increasingly
concentrated.
China Pharmaceutical Distribution Industry Report, 2019-2025
highlights the following:
-
China pharmaceutical distribution industry (development environment,
status quo, market size, market structure, competitive pattern and
development trends) -
China drug retailing market (market size, gross margin, and net
margin, quantity, the share of medical insurance designated stores,
per customer transaction, and comparison of operating results between
major drug retailers) -
20 Chinese pharmaceutical distribution companies (operation, revenue
structure, gross margin, development strategy, etc.).
Key Topics Covered:
1. Overview of Pharmaceutical Distribution Industry
1.1 Definition
1.2 Industry Chain
1.3 Strength and Weakness of Pharmaceutical Chain Enterprises
1.3.1 Strength of Pharmaceutical Chain Enterprises
1.3.2 Weakness of Pharmaceutical Chain Enterprises
2. Pharmaceutical Distribution Industry in China
2.1 Development Environment
2.1.1 Policy
2.1.2 Economy
2.1.3 Medical Institution
2.1.4 Health Expenditure
2.1.5 Aging
2.1.6 Per Capita Disposable Income
2.2 Status Quo
2.3 Market Size
2.4 Market Structure
2.5 Competitive Landscape
2.6 Development Trends
2.6.1 Pharmaceutical E-commerce Becomes an Important Model
2.6.2 Operating Efficiency and Service Functions Gets Improved Constantly
2.6.3 Capital Market Plays a Bigger Role in Integration of Enterprises
2.6.4 Pharmaceutical Supply-chain Management Services Are Upgraded
Rapidly
2.6.5 Cross-border Integration of Pharmaceuticals and E-commerce
Continues
2.6.6 Favorable Policies Make the Market More Concentrated
2.6.7 Growing Trend towards Regionalization
2.6.8 Wholesale-retail Integration Spurs Industry Consolidation
2.6.9 Outflow of Prescriptions is a Boon for the Industry
2.6.10 Single Drugstores are Being Edged out by Drugstore Chains Which
are Gaining Ground
3 Chinese Drug Retail Market
3.1 Market Size
3.2 Gross Margin and Net Margin
3.3 Quantity
3.3.1 Top100 Pharmacy Chains
3.3.2 Online Pharmacy
3.3.3 Independent Pharmacy
3.3.4 Shares of New Stores and Those Shutdown
3.4 Share of Medical Insurance Designated Stores
3.5 Per Customer Transaction
3.6 Comparison of Operating Results between Major Drug Retailers
4. Major Enterprises
4.1 China National Accord Medicines Corporation Ltd.
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Major Customers
4.1.5 Pharmaceutical Distribution Business
4.1.6 Development Strategy
4.2 Nanjing Pharmaceutical Co, Ltd.
4.3 Shanghai No.1 Pharmacy Co, Ltd.
4.4 China National Medicines Corporation Ltd.
4.5 Huadong Medicine Co, Ltd.
4.6 Cachet Pharmaceutical Co, Ltd.
4.7 Jointown Pharmaceutical Group Co, Ltd.
4.8 Realcan Pharmaceutical Co, Ltd.
4.9 Shanghai Pharmaceuticals Holding Co, Ltd.
4.10 Zhejiang Int’l Group Co, Ltd.
4.11 Zhejiang Zhenyuan Share Co, Ltd.
4.12 China Meheco Co, Ltd.
4.13 Charmacy Pharmaceutical Co, Ltd.
4.14 Luyan Pharma Co, Ltd.
4.15 China Resources Pharmaceutical Group Limited
4.16 DaShenLin Pharmaceutical Group Co, Ltd.
4.17 Yunnan Jianzhijia Health Chain Co, Ltd.
4.18 Yifeng Pharmacy Chain Co, Ltd.
4.20 LBX Pharmacy Chain Co, Ltd
For more information about this report visit https://www.researchandmarkets.com/r/hgappu
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Pharmaceuticals